Hs 578T Xenograft Model Service for Breast Cancer

The Hs 578T xenograft model serves as a highly specialized in vivo translational platform designed to evaluate candidate therapies targeting aggressive, mesenchymal-like triple-negative breast cancers with highly invasive characteristics. Alfa Cytology delivers a comprehensive, end-to-end Hs 578T xenograft model service, combining optimized cell preparation methodologies with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of Hs 578T Xenograft Model for Breast Cancer

The Hs 578T cell line is a well-established human mammary carcinoma model that represents the Claudin-low molecular subtype of triple-negative breast cancer (TNBC). Derived from a primary breast carcinoma, this model is molecularly defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. Notably, Hs 578T cells exhibit a distinct stellate, mesenchymal morphology and harbor a detrimental mutation in the TP53 gene, alongside an activating mutation in the HRAS oncogene (G12D). This unique genomic landscape imparts a highly migratory, invasive, and stem-like phenotype to the cells, making the Hs 578T model a vital preclinical instrument for exploring epithelial-to-mesenchymal transition (EMT) pathways, tumor angiogenesis, and for validating novel targeted small molecules or advanced combination immunotherapies.

When established in vivo as a xenograft in immunocompromised mice, Hs 578T cells form solid subcutaneous or orthotopic tumors that faithfully mirror the poorly differentiated histological features and hyper-aggressive clinical presentation of human receptor-negative malignancies. To overcome variable growth characteristics inherent to mesenchymal-like lines, cell inoculation requires meticulous calibration. The resulting model provides stable engraftment and reliable, linear growth kinetics, serving as a high-sensitivity testing matrix for preclinical efficacy screening, biomarker identification, and pharmacodynamic (PK/PD) profiling.

Cell Line Information: Hs 578T

The Hs 578T cell line maintains a distinct fibroblast-like, mesenchymal morphology in vitro and reliably preserves its primary triple-negative receptor profile and malignant genomic signatures upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the Hs 578T model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the Hs 578T Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in claudin-low/mesenchymal-like triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of Hs 578T Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the Hs 578T xenograft model:

• Cell Culture & Quality Control: Hs 578T cells are cultivated in optimized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of Hs 578T cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. Hs 578T Xenograft Model Construction Workflow

Case Study - Hs 578T Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the Hs 578T xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule inhibitor designed to target mesenchymal tumor proliferation. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Why Choose Alfa Cytology?

Choosing the right partner for your highly invasive, triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against highly invasive, triple-negative breast cancer using the robust Hs 578T xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.